<DOC>
	<DOCNO>NCT01724385</DOCNO>
	<brief_summary>To evaluate efficacy intravitreal bevacizumab injection treatment proliferative diabetic retinopathy ( PDR ) new dense vitreous hemorrhage ( VH ) previous full panretinal photocoagulation ( PRP ) .</brief_summary>
	<brief_title>Intravitreal Bevacizumab Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description>The investigator carry prospective study patient PDR prior complete laser treatment present new dense VH . All eye treat intravitreal injection bevacizumab ( 1.25 mg ) . Complete ophthalmic examination and/or ocular ultrasonography perform baseline 1 , 6 , 12 week 6 , 9 , 12 month first injection . Re-injection do non-clearing recurrent VH .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Vitreous Hemorrhage</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>patient diabetes mellitus proliferative diabetic retinopathy prior complete panretinal photocoagulation present new dense vitreous hemorrhage oneeyed patient previous intraocular surgery severe lens opacity preclude fundus examination advance glaucoma history thromboembolic event myocardial infarction cerebrovascular accident uncontrolled systemic hypertension , systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg know coagulation abnormality current use anticoagulant medication aspirin know allergy relevant drug study evidence external ocular infection conjunctivitis significant blepharitis .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>bevacizumab ,</keyword>
	<keyword>proliferative diabetic retinopathy ,</keyword>
	<keyword>vitreous hemorrhage ,</keyword>
</DOC>